October 25, 2012 — Lantheus Medical Imaging Inc. announced it has extended its contract with Nordion to supply molybdenum-99 (Mo-99) for use in its TechneLite (Technetium Tc-99m) generators. Mo-99 is the parent isotope of technetium-99m (Tc-99m), the medical radioisotope most widely used in nuclear medicine diagnostic imaging tests.
“As a leading provider of radioisotope generators, securing the supply of critical isotopes such as Mo-99 is of prime importance to the success of our business,” said Don Kiepert, president and CEO of Lantheus Medical Imaging. “Our amended contract with Nordion further solidifies our globally diversified sourcing of Mo-99, which reinforces our ongoing commitment to provide a stable, balanced and reliable supply to our customers.”
“One of Nordion’s key priorities is providing a continuous supply of medical isotopes to meet the needs of the global medical community, and the extension of our Mo-99 supply contract with Lantheus further advances this objective,” said Steve West, CEO of Nordion. “We value the ongoing relationship with Lantheus and are focused on identifying new isotope sources to provide a stable supply chain for our partners worldwide.”
Tc-99m is a critical component of many medical tests, including scans of the heart, brain, kidneys and some types of tumors. Tc-99m is used in Lantheus’ TechneLite generators, which are distributed to hospitals and radiopharmacies as a source of Tc-99m for diagnostic imaging procedures. Tc-99m is also used with Cardiolite (Kit for the Preparation of Technetium Tc 99m Sestamibi for Injection).
For more information: www.lantheus.com, www.nordion.com
October 05, 2023 
![Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)](/sites/default/files/styles/content_feed_medium/public/Screen%20Shot%202022-09-13%20at%203.30.13%20PM.png?itok=2w6OoNd6)
